Pharmaceuticals

Corcept Therap

Corcept Therapeutics Reports Q1 2025 Earnings

Corcept Therapeutics released FY2026 Q1 earnings on April 30 After-Market (EST), actual revenue USD 164.9 M (forecast USD 186.61 M), actual EPS USD -0.3041 (forecast USD -0.138)

Corcept ALS Drug Trial Shows 87% Reduction in Mortality Risk

Corcept Therapeutics to Release Q1 2026 Earnings with Executives and Directors Trading Stocks

Boston Trust Walden Corp Reduced Holdings in Corcept Therapeutics

Corcept Therap to release FY2026 Q1 earnings on April 30 After-Market EST, forecast revenue USD 186.61 M, EPS USD -0.142

Corcept to present new subgroup analysis of Lifyorli's Phase 3 ROSELLA trial

Corcept Presents Data Showing Significant Survival Improvement with Lifyorli™ Combination Therapy

Corcept COO William Guyer sells 20,000 shares

FDA Approves Corcept's Lifyorli for the Treatment of Invasive Ovarian Cancer

Corcept Therapeutics Director Buys Company Shares

Corcept Therapeutics released FY2025 Q4 earnings on February 24 After-Market EST, actual revenue USD 202.13 M (forecast USD 254.94 M), actual EPS USD 0.2002 (forecast USD 0.2712)

Corcept Therapeutics released FY2025 Annual Earnings on February 24 After-Market (EST), Actual Revenue USD 761.41 M (Forecast USD 814.21 M), Actual EPS USD 0.82 (Forecast USD 0.956)

Corcept Reports Q4 2025 Earnings with Revenue Growth, Plans NDA Submission for Ovarian Cancer Drug in 2026

Corcept Therapeutics to Release FY2025 Q4 Earnings on February 24 After-Market (EST), Forecast Revenue USD 254.94M, EPS USD 0.2712

Corcept Therapeutics' Chief Development Officer William Guyer Disposes of Company Common Stock

Corcept Announces Positive Results for Relacorilant and Nab-Paclitaxel Combination in Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Announces Successful ROSELLA Trial for Ovarian Cancer Drug

Corcept's Experimental Cancer Drug Reaches Primary Goal in Late-Stage Study

Hagens Berman Launches Investigation Into Corcept Therapeutics

Optimi Health

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

CORT

LABU

SBIO

UBS Group upgraded Corcept Therapeutics, citing increased confidence in its ovarian cancer therapy, Lifyoril. This upgrade, alongside insider share gifting, highlights Corcept's evolving profile. While optimism grows around Lifyoril's regulatory outlook, risks remain from Korlym generics and earnings volatility. Analysts project significant revenue growth, with a fair value estimate of $73.40, indicating a potential 30% upside from current prices. Investors should consider both the positive developments and ongoing challenges as they evaluate Corcept's investment narrative.

Simplywall

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

UBS Group AG

Teva Pharmaceutical Industries

NVIDIA

Microsoft

NVIDIA Corporation

Does Corcept Therapeutics' (CORT) UBS Upgrade and Insider Gifting Reframe Its Oncology Ambitions?

CRGT

Corti has launched its Startup Acceleration Program to support healthcare AI startups in overcoming regulatory barriers, particularly in Europe. The program offers access to its clinical-grade AI model, Symphony, which has outperformed OpenAI on HealthBench. With increasing compliance pressures, Corti aims to assist founders in navigating the complex regulatory landscape, providing resources and support to help them scale their innovations. Applications for the program are now open to pre-seed through Series B companies in healthcare and adjacent life sciences.

prnewswire

Cortigent, Inc.

VG Health

OpenAI

12:30 ETCorti steps up its support for the next wave of healthcare startups as OpenAI pushes into the space and others retreat from Europe

ARKG

Zacks Research upgraded Corcept Therapeutics (NASDAQ:CORT) from a "strong sell" to a "hold" rating. Other analysts have also raised their ratings, with Truist Financial giving a "strong-buy" and Canaccord Genuity increasing the price target from $100 to $110. The stock opened at $51.37, with a market cap of $5.51 billion. Corcept reported a quarterly EPS of ($0.30), missing estimates, but revenue increased 4.9% year-over-year. Insider trading activity included a significant purchase by Director G Leonard Baker, Jr. and a sale by CEO Joseph K. Belanoff.

Market Beat

Health Care Select Sector SPDR

iShares US Pharma

iShares Global Healthcare

Ark Genomic Revolution ETF

Corcept Therapeutics (NASDAQ:CORT) Upgraded by Zacks Research to Hold Rating

Corcept Therapeutics (CORT) is currently priced at approximately $51.42, following significant volatility in its share price. The stock has shown mixed performance, with a year-to-date gain of 34.6% but a 29.3% decline over the past year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by about 84.4%, estimating an intrinsic value of $329.41 per share. However, its P/E ratio of 120.36x is significantly higher than industry averages, indicating it may be overvalued. Investors are encouraged to consider various valuation narratives to assess their investment strategy.

Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Volatility In The Share Price

Corcept Therapeutics shares are trading higher after the company announced results from its phase 2 DAZALS trial of dazucorilant for amyotrophic lateral sclerosis.

benzinga_article

Corcept Therapeutics shares rose after the Phase 2 DAZALS study showed an 87% reduction in death risk for ALS patients treated with 300 mg of dazucorilant daily. Despite missing its primary endpoint, the study indicated improved survival rates. The company reported a loss of 30 cents per share and revenue of $164.9 million, both below expectations, but raised its 2026 sales outlook to $950 million-$1.05 billion. The stock is currently up 3.37% at $48.09, reflecting mixed performance metrics in value, quality, and momentum.

Colgate

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics reported Q1 2026 revenue of $164.9 million, up from $157.2 million year-over-year, and raised its full-year guidance to $950 million to $1.05 billion. The company faced a net loss of $31.8 million compared to a net income of $20.5 million last year. Significant growth in demand for hypercortisolism medications is expected to boost future revenues, alongside the FDA approval of Lithioli for ovarian cancer, projected to exceed $1 billion in annual revenue by 2030. Management expressed confidence in strategic growth across endocrinology and oncology divisions.

Corcept Therapeutics Q1 2026 Earnings Call Transcript

Corcept Therapeutics will announce its earnings results this Thursday after market hours. Last quarter, the company missed revenue expectations, reporting $202.1 million, an 11.1% year-on-year increase. Analysts expect an 18.3% revenue growth this quarter. Despite past misses, analysts have reaffirmed their estimates, indicating stable expectations. Corcept's stock has risen 24.9% over the past month, reflecting positive investor sentiment in the pharmaceutical sector. The company is the first among its peers to report earnings this season, making it a key indicator for the industry.

Stock Story

Corcept Earnings: What To Look For From CORT

Corcept Therap(CORT.US)